|Awarded On||December 05, 2012|
|Title||MAPK4 Activates AR and Promotes Castration-Resistant Prostate Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Feng Yang|
Prostate cancer is the most common cancer and the second leading cause of cancer death in American men. Activated Androgen Receptor (AR) is essential for the growth/survival of human prostate cancer. Therefore, androgen-ablation therapy is a standard therapy for advanced and metastatic prostate cancer. However, most initially regressed prostate cancer will relapse and become castration-resistant prostate cancer (CRPC). Interestingly, most CRPCs maintain functional AR; therefore, AR remains a valid therapeutic target for CRPC. However, even with the best available androgen-blockage agents, including the recently FDA-approved Zytiga, there is still no cure for CRPC. Hormone-independent AR act...